AllianceBernstein
SYRE icon

AllianceBernstein’s Spyre Therapeutics SYRE Stock Holding History

AllianceBernstein’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
92,540
+21,640
+31% +$1.58M ﹤0.01% 1587
2026
Q1 		$2.32M Buy
70,900
+3,400
+5% +$128K ﹤0.01% 1910
2025
Q4 		$2.21M Buy
67,500
+31,270
+86% +$817K ﹤0.01% 1940
2025
Q3 		$607K Hold
36,230
– – ﹤0.01% 2576
2025
Q2 		$542K Hold
36,230
– – ﹤0.01% 2597
2025
Q1 		$585K Hold
36,230
– – ﹤0.01% 2496
2024
Q4 		$843K Hold
36,230
– – ﹤0.01% 2407
2024
Q3 		$1.07M Hold
36,230
– – ﹤0.01% 2293
2024
Q2 		$852K Buy
+36,230
New +$1.22M ﹤0.01% 2390
2022
Q2 		– Sell
-864
Closed -$50K – 3372
2022
Q1 		$50K Sell
864
-160
-16% -$13.4K ﹤0.01% 3174
2021
Q4 		$122K Hold
1,024
– – ﹤0.01% 3169
2021
Q3 		$204K Hold
1,024
– – ﹤0.01% 3084
2021
Q2 		$178K Buy
1,024
+88
+9% +$16K ﹤0.01% 3178
2021
Q1 		$185K Sell
936
-20
-2% -$3.84K ﹤0.01% 3077
2020
Q4 		$188K Sell
956
-116
-11% -$24K ﹤0.01% 3004
2020
Q3 		$190K Buy
1,072
+80
+8% +$14.8K ﹤0.01% 2966
2020
Q2 		$229K Buy
992
+592
+148% +$113K ﹤0.01% 2969
2020
Q1 		$47K Buy
+400
New +$68K ﹤0.01% 3061

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

AllianceBernstein's SYRE Position: Q2 2026 in Review

AllianceBernstein increased its Spyre Therapeutics (SYRE) stake by 31% in Q2 2026, buying an estimated $1.58M and bringing the position to 92,540 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

AllianceBernstein first reported a position in SYRE in Q1 2020 and has held it in 18 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • AllianceBernstein held 92,540 shares of Spyre Therapeutics worth $4.67M as of Q2 2026.
  • AllianceBernstein bought 21,640 Spyre Therapeutics shares in Q2 2026, an estimated $1.58M.
  • Spyre Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1587 holding.
  • AllianceBernstein first reported a position in Spyre Therapeutics in Q1 2020 and has held it in 18 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.